INSTIL BIO INC - US IND SUBMISSION FOR SYN-2510 TARGETED IN LATE 2024, STARTING WITH PHASE 2 TRIAL OF SYN-2510 MONOTHERAPY IN SECOND-LINE NSCLC

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.